Your browser doesn't support javascript.
loading
Specific immune modulation of experimental colitis drives enteric alpha-synuclein accumulation and triggers age-related Parkinson-like brain pathology.
Grathwohl, Stefan; Quansah, Emmanuel; Maroof, Nazia; Steiner, Jennifer A; Spycher, Liz; Benmansour, Fethalla; Duran-Pacheco, Gonzalo; Siebourg-Polster, Juliane; Oroszlan-Szovik, Krisztina; Remy, Helga; Haenggi, Markus; Stawiski, Marc; Selhausen, Matthias; Mailver, Pierre; Wolfert, Andreas; Emrich, Thomas; Madaj, Zachary; Su, Arel; Escobar Galvis, Martha L; Mueller, Christoph; Herrmann, Annika; Brundin, Patrik; Britschgi, Markus.
Afiliação
  • Grathwohl S; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Quansah E; Parkinson's Disease Center, Department of Neurodegenerative Science, Van Andel Institute, 333 Bostwick Ave. NE, Grand Rapids, MI, USA United States.
  • Maroof N; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Steiner JA; Parkinson's Disease Center, Department of Neurodegenerative Science, Van Andel Institute, 333 Bostwick Ave. NE, Grand Rapids, MI, USA United States.
  • Spycher L; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Benmansour F; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Duran-Pacheco G; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Siebourg-Polster J; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Oroszlan-Szovik K; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Remy H; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Haenggi M; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Stawiski M; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Selhausen M; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Mailver P; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Wolfert A; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg, Germany Germany.
  • Emrich T; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg, Germany Germany.
  • Madaj Z; Parkinson's Disease Center, Department of Neurodegenerative Science, Van Andel Institute, 333 Bostwick Ave. NE, Grand Rapids, MI, USA United States.
  • Su A; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Escobar Galvis ML; Parkinson's Disease Center, Department of Neurodegenerative Science, Van Andel Institute, 333 Bostwick Ave. NE, Grand Rapids, MI, USA United States.
  • Mueller C; Institute of Pathology, University of Bern, Murtenstrasse 31, Bern, Switzerland Switzerland.
  • Herrmann A; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
  • Brundin P; Parkinson's Disease Center, Department of Neurodegenerative Science, Van Andel Institute, 333 Bostwick Ave. NE, Grand Rapids, MI, USA United States.
  • Britschgi M; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, Switzerland Switzerland.
Free Neuropathol ; 22021 Jan.
Article em En | MEDLINE | ID: mdl-37284635
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Free Neuropathol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Free Neuropathol Ano de publicação: 2021 Tipo de documento: Article